Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P462

A single factor of compliance may not be sufficient to improve outcomes in Ulcerative Colitis

Authors:

W. Kruis*

Evangelisches Krankenhaus Kalk, University of Cologne, Köln, Germany

P463.

Infliximab use in ulcerative colitis from 2003 to 2013: Clinical practice, safety and efficacy

Authors:

L. Fernández-Salazar1, J. Barrio2, C. Muñoz3, J. Legido4, G. González1, R. S-Ocaña2, F. Santos2, B. Velayos1, J.M. González1, 1Hospital Clínico Universitario, Gastroenterology, Valladolid. ACAD, Spain, 2Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain, 3Hospital Virgen de la Salud, Gastroenterology, Toledo. ACAD, Spain, 4Complejo Asistencial de Segovia, Gastroenterology, Segovia. ACAD, Spain

P463. Clinical risk factors for Crohn's disease postoperative recurrence are reflected in alterations in mucosally adherent microbiota at surgical resection
P463. Investigation on patient assessment of adalimumab self-injection treatment – a multicenter patient questionnaire Pearl survey
Authors:

N. Kubokura1, F. Hirai2, K. Watanabe3, M. Esaki1, S. Nakamura4, Y. Yano2, N. Kamata3, M. Iimuro4, H. Yamagami3, T. Matsumoto1, T. Matsumoto4, T. Matsui2, 1Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 2Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, 3Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, 4Hyogo College of Medicine, Department of Lower Gastroenterology, Hyogo, Japan

P463

Achieving Remission in Paediatric Inflammatory Bowel Disease (pIBD): Data on Mono- vs. Combination Therapy using the ImproveCareNow (ICN) Data Base

Authors:

S. Chadokufa*1, B. Huggett1, S. Sider1, N. Shah1, M. Elawad1, F. Kiparissi1, 2

1Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom, 2University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom

P464.

Infliximab optimisation in ulcerative colitis: Intensificated and deintensificated patients clinical outcome

Authors:

L. Fernández-Salazar1, J. Barrio2, J. Legido3, C. Muñoz4, G. González1, R. S-Ocaña2, F. Santos2, B. Velayos1, J.M. González1, 1Hospital Clínico Universitario, Gastroenterology, Valladolid. ACAD, Spain, 2Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain, 3Complejo Asistencial de Segovia, Gastroenterology, Segovia. ACAD, Spain, 4Hospital Virgen de la Salud, Gastroenterology, Toledo. ACAD, Spain

P464. Dysbiosis in mucosally adherent microbiota at surgery and in post-endoscopic recurrence at 6 and 12 months – a longitudinal prospective evaluation in Crohn's disease
P464. Investigation of adherence to adalimumab self-injection treatment – a multicenter patient questionnaire Pearl survey
Authors:

F. Hirai1, K. Watanabe2, N. Kubokura3, M. Iimuro4, Y. Yano1, N. Kamata2, M. Esaki3, H. Yamagami2, S. Nakamura4, T. Matsumoto3, T. Matsumoto4, T. Matsui1, 1Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, 2Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, 3Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 4Hyogo College of Medicine, Department of Lower Gastroenterology, Hyogo, Japan

P464

Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis in Korea: The 1999-2005 cohort

Authors:

H.-S. Lee1, S.-K. Yang1, K. Chang2, H. Seo*1, H. So1, J.S. Soh2, S. Lee2, J.H. Bae1, H.J. Lee2, S.H. Park1, D.-H. Yang2, K.-J. Kim1, B.D. Ye2, J.-S. Byeon1, S.-J. Myung1

1University of Ulsan Collage of Medicine, Asan Medical Center , Gastroenterology, Seoul, Korea, Republic of, 2University of Ulsan Collage of Medicine, Asan Medical Center, Gastroenterology, Seoul, Korea, Republic of

P465.

IL-4 in pathogenesis of systematic manifestations of ulcerative colitis

Authors:

V. Pavlenko, K. Gulnara, 1Stavropol State Medical Institute, Stavropol, Russian Federation, 2University, Medical, Stavropol, Russian Federation

P465. Are patients with inflammatory bowel disease more at risk of developing traveller's diarrhoea?
P465. Intravenous tacrolimus therapy can rapidly induce remission in refractory ulcerative colitis
Authors:

T. Fujii1, M. Naganuma2, E. Saito1, M. Nagahori1, K. Ohtsuka1, M. Watanabe1, 1Tokyo Medical and Dental University, Gastroenterology and Hepatology, Tokyo, Japan, 2Keio University School of Medicine, Gastroenterology, Tokyo, Japan

P465

Inadequate immunisation against viral hepatitis B and no detected cases of hepatits C infection among patients with Inflammatory Bowel Disease

Authors:

K. Waszczuk*1, E. Waszczuk2, A. Mulak2, L. Szenborn1, L. Paradowski2

1Wroclaw Medical University, Department of Pediatrics and Infectious Diseases, Wroclaw, Poland, 2Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

P466.

Hypogonadal patients with Crohn's disease benefit from treatment with testosterone – data from an ongoing, long-term, observational registry study

Authors:

F. Saad1, M. Nasser2, G. Doros3, W. Kurtz4, A. Haider5, L. Gooren6, 1Bayer Pharma, Global Medical Affairs Andrology, Berlin, Germany, 2University of Aleppo, Dpt. of Gastroenterology, Aleppo, Syrian Arab Republic, 3Boston University School of Public Health, Dpt. of Epidemiology and Statistics, Boston, United States, 4Klinikum Bremerhaven, Dpt. of Internal Medicine, Bremerhaven, Germany, 5Private Urology Practice, Urology, Bremerhaven, Germany, 6VU medical Center, Dpt. of Internal Medicine, Endocrine section, Amsterdam, Netherlands

P466. Endogenous production of antibiotics by mesenchymal stem cells and the potential value in Crohn's fistula healing
P466. Influenza vaccination uptake in children with inflammatory bowel disease – Is there room to improve?
Authors:

D. Cheema1, R. Muhammed1, 1Birmingham Children's Hospital, Paediatric Gastroenterology, Birmingham, United Kingdom

P466

Not all penetrating events are the same: differences and similarities in patients with or without entero-urinary fistulas.

Authors:

R. Coelho*, F. Magro, S. Lopes, G. Macedo

Centro Hospitalar São João, Gastrenterology, Porto, Portugal

P467.

How often do we discontinue maintenance infliximab due to clinical remission in Crohn's disease?

Authors:

S.J. Budas, J.P. Seenan, N. Jamieson, A. Cahill, J.W. Winter, D.R. Gaya, A.J. Morris, Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom

P467. Infliximab levels in newborns exposed to anti-TNFa during pregnancy for maternal inflammatory bowel disease correlate with gestational age at last drug application
Authors:

D. Duricova1, N. Machkova1, M. Bortlik1, K. Malickova2, L. Hrdlicka1, M. Lukas1, 1Charles University, IBD Clinical and Research Centre, Iscare, Prague, Czech Republic, 2Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty, Prague, Czech Republic

P467. Molecular fingerprinting techniques reveal distinct luminal and mucosa-associated bacterial communities in the human colon